In addition, they observed that specific EC phenotypes were differentially sensitive to anti-VEGF drugs and VEGFR tyrosine kinase inhibitors; tip and breach tumor-associated ECs were more sensitive to VEGF blockade than postcapillary vein and proliferating ECs, and capillary ECs were less sensitive to VEGFR tyrosine kinase inhibitors (14). This evidence concerns the gene VEGFA and neoplasm.